D. E. Shaw & Co., Inc. Iovance Biotherapeutics, Inc. Transaction History

D. E. Shaw & Co., Inc.

$125 Billion
Q2 2025

A detailed history of D. E. Shaw & Co., Inc. transactions in Iovance Biotherapeutics, Inc. stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 55,471 shares of IOVA stock, worth $128,692. This represents 0.0% of its overall portfolio holdings.

Number of Shares

55,471

Previous 39,276 41.23%

Holding current value

$128,692

Previous $130,000 26.92%

% of portfolio

0.0%

Previous 0.0%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	BUY	$1.66 - $3.61 $26,883 - $58,463	16,195 Added 41.23%	55,471 $95,000
Q1 2025 May 15, 2025	BUY	$3.33 - $7.79 $28,185 - $65,934	8,464 Added 27.47%	39,276 $130,000
Q4 2024 Feb 14, 2025	SELL	$7.17 - $12.28 $264,831 - $453,574	-36,936 Reduced 54.52%	30,812 $228,000
Q3 2024 Nov 14, 2024	SELL	$7.28 - $11.9 $4.28 Million - $7 Million	-588,082 Reduced 89.67%	67,748 $636,000
Q2 2024 Aug 14, 2024	SELL	$7.78 - $14.19 $13.2 Million - $24.1 Million	-1,696,336 Reduced 72.12%	655,830 $5.26 Million
Q1 2024 May 15, 2024	BUY	$7.59 - $17.47 $16.2 Million - $37.3 Million	2,137,032 Added 993.35%	2,352,166 $34.9 Million
Q4 2023 Feb 14, 2024	BUY	$3.3 - $8.89 $585,327 - $1.58 Million	177,372 Added 469.71%	215,134 $1.75 Million
Q3 2023 Nov 14, 2023	SELL	$4.44 - $8.79 $3.65 Million - $7.22 Million	-820,994 Reduced 95.6%	37,762 $171,000
Q2 2023 Aug 14, 2023	SELL	$5.36 - $9.06 $8.05 Million - $13.6 Million	-1,501,195 Reduced 63.61%	858,756 $6.05 Million
Q1 2023 May 15, 2023	SELL	$5.53 - $8.22 $10.3 Million - $15.3 Million	-1,861,809 Reduced 44.1%	2,359,951 $14.4 Million
Q4 2022 Feb 14, 2023	BUY	$5.62 - $10.0 $8.58 Million - $15.3 Million	1,526,540 Added 56.64%	4,221,760 $27 Million
Q3 2022 Nov 14, 2022	BUY	$9.53 - $13.11 $5.89 Million - $8.1 Million	617,689 Added 29.73%	2,695,220 $25.8 Million
Q2 2022 Aug 15, 2022	BUY	$6.38 - $18.33 $12.5 Million - $35.8 Million	1,952,904 Added 1567.0%	2,077,531 $22.9 Million
Q1 2022 May 16, 2022	BUY	$12.38 - $19.1 $651,064 - $1 Million	52,590 Added 73.0%	124,627 $2.08 Million
Q4 2021 Feb 14, 2022	BUY	$16.55 - $27.63 $1.03 Million - $1.73 Million	62,523 Added 657.17%	72,037 $1.38 Million
Q3 2021 Nov 15, 2021	SELL	$20.35 - $26.63 $327,065 - $427,997	-16,072 Reduced 62.82%	9,514 $235,000
Q2 2021 Aug 16, 2021	SELL	$16.33 - $33.07 $3.46 Million - $7.02 Million	-212,183 Reduced 89.24%	25,586 $666,000
Q1 2021 May 17, 2021	BUY	$28.67 - $52.59 $3.12 Million - $5.73 Million	108,988 Added 84.63%	237,769 $7.53 Million
Q4 2020 Feb 16, 2021	BUY	$28.04 - $50.26 $2.31 Million - $4.14 Million	82,391 Added 177.61%	128,781 $5.98 Million
Q3 2020 Nov 16, 2020	BUY	$27.75 - $36.3 $545,981 - $714,202	19,675 Added 73.65%	46,390 $1.53 Million
Q1 2020 May 15, 2020	BUY	$19.54 - $38.85 $88,438 - $175,835	4,526 Added 20.4%	26,715 $800,000
Q4 2019 Feb 14, 2020	BUY	$17.95 - $29.41 $398,292 - $652,578	22,189 New	22,189 $614,000
Q4 2018 Feb 14, 2019	SELL	$7.51 - $11.93 $170,882 - $271,455	-22,754 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$11.25 - $17.7 $255,982 - $402,745	22,754 New	22,754 $256,000

Others Institutions Holding IOVA

# of Institutions

297

Shares Held

234M

Call Options Held

1.14M

Put Options Held

1.15M

View Full List

About IOVANCE BIOTHERAPEUTICS, INC.

Ticker IOVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 157,800,992
Market Cap $366M
Description
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment o...

More about IOVA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.

Account